Heidelberg Pharma AG (WBO:HPHA) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HPHA Heidelberg Pharma AG WBO:HPHA
32 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

WBO:HPHA vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Heidelberg Pharma AG's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Short Interest distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Short Interest falls into.


WBO:HPHA
32GF Score
Heidelberg Pharma AG WBO:HPHA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for WBO:HPHA:

  • Short Interest:
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Germany
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score

Get the complete analysis for WBO:HPHA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value